NCT07166601
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07166601
Title M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors (TITER)
Acronym TITER
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors EMD Serono Research & Development Institute, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.